Modification of Insulin-Like Growth Factor 1 Receptor, c-Src, and Bcl-XL Protein Expression During the Progression of Barrett's Neoplasia

Human Pathology

Volumn 34, Issue 10, 2003, Pages 975-982

  Iravani, Shohreh ^b   Zhang, Hong Q ^a   Yuan, Zeng Q ^a   Cheng, Jin Q ^a   Karl, Richard C ^a   Jove, Richard ^a   Coppola, Domenico ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Barrett's neoplasia; Bcl XL; c Src; Esophagus; Insulin like growth factor 1 receptor; Progression

Indexed keywords

CELL CYCLE PROTEIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN C SRC; REGULATOR PROTEIN; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTESTINE METAPLASIA; LYMPH NODE METASTASIS; MITOGENESIS; ONCOGENE SRC; PROTEIN EXPRESSION;

EID: 0142231979     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1053/S0046-8177(03)00354-X     Document Type: Article

References (52)

1. Haggitt R: Barrett's esophagus, dysplasia and adenocarcinoma. HUM PATHOL 25:282-993, 1994
2. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991
3. Dent J, Bremner CG, Collen MJ, et al: Barrett's esophagus: Working party report to the World Congress of Gastroenterology, Sydney, Australia. J Gastroenterol Hepatol 6:1-22, 1991
4. Soslow RA, Petersen CG, Remotti H, et al: Acidic fibroblast growth factor is expressed seqnentially in the progression from Barrett's esophagus to esophageal adenocarcinoma. Dis Esophagus 14: 23-27, 2001
5. Soslow RA, Altorki NK, Yang G, et al: Mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma. Mod Pathol 12:580-586, 1999
6. Swami S, Kumble S, Triadafilopoulos G: E-cadherin expression in gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma: An immunohistochemical and immunoblot study. Am J Gastroenterol 90:1808-1813, 1995
7. Wang LD, Shi ST, Zhou Q. et al: Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastria-cardia carcinogenesis. Int J Cancer 59:514-519, 1994
8. Coppola D, Schreiber RH, Mora L, et al: Significance of Fas and retinoblastoma protein expression during the progression of Barrett's metaplasia to adenocarcinoma. Ann Surg Oncol 6:298-304. 1999
9. Ray GS, Lee JR, Nwokeji K, et al: Increased immunoreactivity for Rab11, a small GTP-binding protein, in low-grade dysplastic Barrett's epithelia. Lab Invest 77:503-511. 1997
10. Barrett MT, Sanchez CA, Galipeau PC, et al: Allelic loss of 9p21 and mutation of the CDK-N2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13: 1867-1873, 1996
11. Al-Kasspooles M, Moore JH, Orringer MB, et al: Amplification and overexpression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas. Int J Cancer 54:213-219, 1993
12. Hughes SJ, Nambu Y, Soldes OS, et al: Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res 57:5571-5578, 1997
13. Kumble S, Omary MB, Cartwright CA, et al: Src activation in malignant and premalignant epithelia of Barrett's esophagus. Gastroenterology 112:348-356, 1997
14. Jankowski J, Coghill G, Hopwood D, et al: Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus. Gut 33:1033-1038, 1992
15. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10:105-115, 1999
16. Soslow RA, Remotti H, Baergen RN, et al: Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus. Mod Pathol 12:239-250, 1999
17. Weber MJ: Malignant transformation by Rous sarcoma virus: From phosphorylation to phenotype. Adv Viral Oncol 4:249-268, 1984
18. Tanno S, Tanno S, Mitsuuchi Y, et al: AKT activation up-regulates insulin-like growth factor-1 receptor expression and promotes invasiveness of human pancreatic cancer cells. Cancer Res 61:589-593, 2001
19. Sell C, Dumenil G, Deveaud C, et al: Effect of a null mutation of the insulin-like growth factor type 1 receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 14: 3604-3612, 1994
20. Coppola D, Ferber A, Miura M, et al: A functional insulin-like growth factor 1 receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol 14:4588-4595, 1994
21. Resnicoff M, Coppola D, Sell C, et al: Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type I insulin-like growth factor receptor. Cancer Res 54:4848-4850, 1994
22. Rubin R, Baserga R: Biology of disease, Insulin-like growth factor-1 receptor: Its role in cell proliferation, apoptosis, and tumorigenicity. Lab Invest 73:311-331, 1995
23. Riddel RH, Goldman H, Ransohoff DF, et al: Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical implications. HUM PATHOL. 14:931-968, 1983
24. Allred DC, Clark GM, Ellfdge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Nat Cancer Inst 85:200-206, 1993
25. Mao W, Irby R, Coppola D, et al: Activation of c-src by receptor tyrosine kinases in human colon cancer cell with high metastatic potential. Oncogene 15:25-33, 1997
26. Pera M, Cameron AJ, Trastek VF, et al: Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology 104:510-513, 1993
27. Levine DO, Haggitt RC, Blount PL, et al: An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology, 105:40-50, 1993
28. Hickey K, Grehan D, Reid IM, et al: Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 74:1693-1698, 1994
29. Nakamura T, Nekarda H, Hoelscher AH, et al: Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer 73:1785-1794, 1994
30. Lord RV, Tsai PI, Danenberg KD, et al: Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence. Surgery 129:267-276, 2001
31. Woodward TA, Klingler PD, Genko PV, et al: Barrett's esophagus, apoptosis and cell cycle regulation: Correlation of p53 with Bax, Bcl-2 and p21 protein expression. Anticancer Res 20:2427-2432, 2000
32. Tselepis C, Perry I, Jankowski J: Barrett's esophagus: Dysregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasia-carcinoma sequence. Digestion 61:1-5, 2000
33. Hanas JS, Lerner MR, Lightfoot SA, et al: Expression of the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett's esophagus. Cancer 86:756-763, 1999
34. c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci U S A 84:2251-2255, 1987
35. Jove R, Hanfusa H: Cell transformation by the viral Src oncogene. Ann Rev Cell Biol 3:31-56, 1987
36. c-src activation in human colon carcinoma. J Clin Invest 83:2065-2033, 1989
37. Garcia R, Bowman TL, Niu G, et al: Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513, 2001
38. Masaki T, Tokuda M, Shiratori Y, et al: A possible novel src-related tyrosine kinase in cancer cells of LEC rats that develop hepatocellular carcinoma. J Hepatol 32:92-99, 2000
39. Irby RB, Mao W, Coppola D, et al: Activating Src mutation in a subset of advanced human colon cancers. Nat Genet 21:187-190, 1999
40. Cooper JA, Howell B: The when and how of src regulation. Cell 73:1051-1054, 1993
41. Xu W, Harrison SC, Eck MJ: Three-dimensional structure of the tyrosine kinase c-Src. Nature 385:595-602, 1997
42. Iravani S, Mao W, Ling F, et al: Elevated c-Src protein expression is an early event in colonic neoplasia. Lab Invest 78:365-371, 1998
43. Resnicoff M, Ambrose D. Coppola D, et al: Insulin-like growth factor-1 and its receptor mediate the autocrine proliferation of human ovarian carcinoma cell lines. Lab Invest 69:756-760, 1993
44. Ambrose D, Resnicoff M, Coppola D, et al: Growth regula tion of human glioblastoma T98G cells by insulin-like growth factor-1 (IGF-1) and the IGF-1 receptor. J Cell Physiol 159:92-100, 1994
45. Peruzzi F, Prisco M, Dews M, et al: Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection of apoptosis. Mol Cell Biol 19:7203-7215, 1999
46. Surmacz E, Sell C, Swantek J, et al: Dissociation of mitogenesis and transforming activity by C-terminal truncation of the insulin-like growth factor I receptor. Exp Cell Res 218:370-380, 1995
47. Faria TN, Blakesley VA, Kato H, et al: Role of the carboxyterminal domains of the insulin and insulin-like growth factor I receptors in receptor function. J Biol Chem 269:13922-13928, 1994
48. O'Connor R, Kauffmann-Zeh A, Liu Y, et al: Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 17:427-435, 1997
49. Boise LH, Gonzalez-Garcia M, Postema CE, et al: bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597-608, 1993
50. L expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 18:4654-4662, 1999
51. Valentinis B, Morrione A, Taylor SJ: Insulin-like growth factor I receptor signaling in transformation by Src oncogenes. Mol Cell Biol 17:3744-3754, 1997
52. Singleton JR, Dixit VM, Feldman EL: Type 1 insulin-like growth factor receptor activation regulates apoptotic proteins. J Biol Chem 271:31791-31794, 1996